Meeting
2021 ASCO Annual Meeting
Risk of immunosuppression and hospitalization after checkpoint inhibitor therapy in patients with cancer and radiation therapy.
Authors
Kate E Lee
Columbia University Vagelos College of Physicians and Surgeons, New York, NY
Kate E Lee , David Andrew Bender , Catherine S. Spina , Brigham Hyde , Adam S Faye , Simon Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2588)
DOI
10.1200/JCO.2021.39.15_suppl.2588
Abstract #
2588
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.
First Author: Guillermo de Velasco
Poster
2023 ASCO Annual Meeting
The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.
First Author: Elizabeth Faour
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Annual Meeting
Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment.
First Author: Sarah Kim